[Hemodynamic study, under hot and cold conditions, of the digital artery in arterial hypertension and the effects of cardioselective and non-cardioselective beta blocker treatment].
The finger systolic pressure of 25 healthy subjects and 23 hypertensives was studied by plethysmography at 30 degrees, 15 degrees and 10 degrees centigrade. The hypertensive group was given equipotent doses of either Metoprolol or Propranolol in accordance with a double-blind cross-over protocol including a washout period. The fall in systolic pressure between the brachial artery in the upper arm and the digital artery was significantly increased in the hypertensive group as compared to healthy controls; the rise persisted under hot and hyperemic conditions and remained constant during both betablocker treatments. In the hypertensive group digital arterial tone increased under cold conditions before any treatment; this abnormality did not vary under Metoprolol but intensified significantly under Propranolol. Finger plethysmography made it possible to show and quantify the peripheral vascular repercussions of hypertension on the digital artery and evaluate the changes induced by treatments. It also helps to clarify the physiopathology of certain side effects caused by betablockers and might to some extent help in the choice and the survey of treatment and in the subsequent follow-up.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D001158:Arteries; D003080:Cold Temperature; D005260:Female; D005385:Fingers / Q000098:blood supply*; D006439:Hemodynamics / Q000187:drug effects; D006358:Hot Temperature; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D010991:Plethysmography; D011433:Propranolol / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D011433:Propranolol; D008790:Metoprolol
Etude hémodynamique au chaud et au froid de l'artère digitale dans l'hypertension artérielle et influence des traitements bêtabloquants cardio-sélectifs et non cardio-sélectifs.